Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.48 |
| ▸ | RAF1 | P04049 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 4/20 | 0.48 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20395167 | 0.87 | EGFR (0.61) | EGFRERBB2MAP2K1RAF1SRC | |
| SCHEMBL4460993 | 0.84 | EGFR (0.69) | EGFRERBB2MAP2K1RAF1SRC | |
| SCHEMBL20395260 | 0.84 | EGFR (0.70) | EGFRERBB2MAP2K1RAF1 | |
| SCHEMBL4461374 | 0.81 | EGFR (0.67) | EGFRERBB2MAP2K1RAF1 | |
| SCHEMBL4472588 | 0.81 | ERBB2 (0.58) | EGFRERBB2MAP2K1RAF1 | |
| SCHEMBL4462173 | 0.81 | EGFR (0.56) | EGFRERBB2MAP2K1RAF1SRC | |
| SCHEMBL4471139 | 0.81 | EGFR (0.61) | EGFRERBB2MAP2K1RAF1SRC | |
| SCHEMBL4463961 | 0.81 | ERBB2 (0.63) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL20395288 | 0.80 | EGFR (0.73) | EGFRERBB2MAP2K1RAF1ERBB4 | |
| SCHEMBL4465543 | 0.80 | ERBB2 (0.50) | EGFRERBB2MAP2K1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | EGFR 166/4885ERBB2 1183/4885MAP2K1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.